micronavigation ELN path item Leukemias path item CLL path item Publications  · 


  1. Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ: Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
    Haematologica 2005; 90(10): 1357-64
    Subjects: CLL
  2. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK von Bergwelt-Baildon M, Debey S, Hallek M, Schultze JL.: Reduced frequencies and suppressive function of CD4+ CD25hi regulatory T cells in patients with chronic lymphocytic leukaemia after therapy with fludarabine.
    Blood 106(6): 2018-25, 2005
    Subjects: CLL
  3. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Dohner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K: Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukaemia
    Blood 2006; 107 (3)
    Subjects: CLL
  4. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jaeger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Doehner H, Brittinger G, Emmerich B, Hallek M: Fludarabine plus cyclophosphamide versus fludarabine alone in first line hterapy of younger patients with chronic lymphocytic leukemia
    Blood 2005, Oct 11
    Subjects: CLL
  5. Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinkothe T, Stutzer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek m, Engert A: Fludarabine in combination with Alemtuzumab is effective and feasible in patients with relapsed or refractory B cell chronic lymphocytic leukaemia: results of a phase II trial
    J Clin Oncol 2005; 23(28): 7024-31
    Subjects: CLL
  6. Hallek M, Stahel RA, Greil R: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia
    Ann Oncol 2005; 6 (suppl 1): 150-51
    Subjects: CLL
  7. Hallek M: Chemoimmunotherapy – towards real progress in the treatment of chronic lymphocytic leukaemia
    Nat Clin Pract Oncol 2005; 2(7): 338-339
    Subjects: CLL
  8. Hallek M: Chronic lymphocytic leukaemia (CLL): First-line treatment
    Hematology 2005; 285-91
    Subjects: CLL
  9. Mayr C, Bund D, Schlee M, Bamberger, Kofler D, Hallek M, Wendtner CM: Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M, Wendtner CM
    Blood 2005, 105(4): 1566-73
    Subjects: CLL
  10. Mayr C, Kofler DM, Buning H, Bund D, Hallek M, Wendtner CM: Transduction of CLL cells by CD40 ligand (CD40L) enhances an antigen specific immune recognition by autologous T cells
    Blood 2005 Nov 1; 106(9): 3223-3226
    Subjects: CLL
  11. Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, Hallek M, Wendtner CM: Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia
    Blood 2005, Sep 22
    Subjects: CLL
  12. Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E: Chronic lymphocytic leukaemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies
    Haematologica 2005; 90 (3): 391-399
    Subjects: CLL
  13. Schmid C, Diem H, Herrmann K, Voltz R, Ott G, Hallek M: Unusual sites of malignancies: CASE 2. Central neurogenic hyperventilation as a complication of Richter’s syndrome
    J Clin Oncol 2005; 23(9): 2096-8
    Subjects: CLL


Print this Document   Sitemap   Contact  
EUTOS for CML is a unique collaboration between the European LeukemiaNet and Novartis Oncology in Europe More ...